IGMPI India

October 7, 2015

October 7, 2015

PAN Drugs receives warning letter from USFDA

USFDA has recently issued a warning letter to PAN drugs Vadodara based plant due to significant deviations from good manufacturing practices.

MHRA issues recall notice of Lacri-Lube eye ointment

The Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a recall notice to Allergen Limited. The recall notice relates to 5g and 3.5g pack sizes of

Another Import Ban for Polydrug Laboratories

USFDA (Food and Drug Administration) issues import ban for products manufactured by Polydrug Laboratories. It was issued on Sept. 11, 2015 for

Health Canada lifts its ban from two Apotex facilities in India

Health Canada has lifted its ban from Apotex two Indian facilities. Canada’s drug regulator reinspected the two plants in June and determined

33 drugs were found to be of not of standard quality during Surprise inspection

Recently Karnataka drug control department had conducted surprise inspections to pick up drug samples at random. The drug test labs have issued their result.

Vivimed Labs successfully completes USFDA inspection of its manufacturing facility

Vivimed Labs has recently successfully completed inspection of its API manufacturing facility in Spain. After the completion of inspection Vivimed said “the USFDA inspectors concluded

GMP News & Guidelines Archives:

VIEW HERE

Parabolic Drugs obtains European GMP certification

Parabolic Drugs announced that the company has received European GMP certification for its Derabassi and Lalru plant. The worksite located at Derabassi is engaged in manufacturing of Cephalosporin products (Certificate No. DE_RP_01_ GMP_2014_0023) and the plant located in Lalru is engaged in manufacturing of Non-beta Lactams products (Certificate No. DE_RP_01_ GMP_2014_0024).

Parabolic Drugs (PDL) has started its commercial operations in 1998 with contract manufacturing of APIs and API intermediates for sales in India and abroad (including regulated markets). At present, Parabolic Drugs has four facilities consisting of three manufacturing plants i.e. Derabassi, Chachrauli (both Punjab) and Panchkula and a Research & Development centre at Barwala (both Haryana).